These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25943562)

  • 1. Dissolved carbon dioxide determines the productivity of a recombinant hemagglutinin component of an influenza vaccine produced by insect cells.
    Meghrous J; Khramtsov N; Buckland BC; Cox MM; Palomares LA; Srivastava IK
    Biotechnol Bioeng; 2015 Nov; 112(11):2267-75. PubMed ID: 25943562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process.
    Buckland B; Boulanger R; Fino M; Srivastava I; Holtz K; Khramtsov N; McPherson C; Meghrous J; Kubera P; Cox MM
    Vaccine; 2014 Sep; 32(42):5496-502. PubMed ID: 25131727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a simple and high-yielding fed-batch process for the production of influenza vaccines.
    Meghrous J; Mahmoud W; Jacob D; Chubet R; Cox M; Kamen AA
    Vaccine; 2009 Dec; 28(2):309-16. PubMed ID: 19879996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FluBlok, a next generation influenza vaccine manufactured in insect cells.
    Cox MM; Hollister JR
    Biologicals; 2009 Jun; 37(3):182-9. PubMed ID: 19297194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage.
    Hickey JM; Holtz KM; Manikwar P; Joshi SB; McPherson CE; Buckland B; Srivastava IK; Middaugh CR; Volkin DB
    J Pharm Sci; 2014 Mar; 103(3):821-7. PubMed ID: 24425059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a scale-up strategy for Chinese hamster ovary cell culture processes using the k
    Doi T; Kajihara H; Chuman Y; Kuwae S; Kaminagayoshi T; Omasa T
    Biotechnol Prog; 2020 Sep; 36(5):e3000. PubMed ID: 32298540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insect larvae biofactories as a platform for influenza vaccine production.
    Gomez-Casado E; Gomez-Sebastian S; Núñez MC; Lasa-Covarrubias R; Martínez-Pulgarín S; Escribano JM
    Protein Expr Purif; 2011 Sep; 79(1):35-43. PubMed ID: 21421054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.
    Treanor JJ; Essink B; Hull S; Reed S; Izikson R; Patriarca P; Goldenthal KL; Kohberger R; Dunkle LM
    Vaccine; 2013 Nov; 31(48):5760-5. PubMed ID: 24075920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.
    Iyer V; Liyanage MR; Shoji Y; Chichester JA; Jones RM; Yusibov V; Joshi SB; Middaugh CR
    Hum Vaccin Immunother; 2012 Apr; 8(4):453-64. PubMed ID: 22370514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for improved dCO2 removal in large-scale fed-batch cultures.
    Mostafa SS; Gu X
    Biotechnol Prog; 2003; 19(1):45-51. PubMed ID: 12573005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor.
    Sun B; Yu X; Kong W; Sun S; Yang P; Zhu C; Zhang H; Wu Y; Chen Y; Shi Y; Zhang X; Jiang C
    Appl Microbiol Biotechnol; 2013 Feb; 97(3):1063-70. PubMed ID: 22945265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
    Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
    Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel recombinant influenza vaccine in insect cells.
    McPherson CE
    Biologicals; 2008 Nov; 36(6):350-3. PubMed ID: 18804387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor.
    Chu C; Lugovtsev V; Lewis A; Betenbaugh M; Shiloach J
    Vaccine; 2010 Oct; 28(44):7193-201. PubMed ID: 20800699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A semi-empirical mathematical model useful for describing the relationship between carbon dioxide, pH, lactate and base in a bicarbonate-buffered cell-culture process.
    Gramer MJ; Ogorzalek T
    Biotechnol Appl Biochem; 2007 Aug; 47(Pt 4):197-204. PubMed ID: 17362203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.
    Keitel WA; Treanor JJ; El Sahly HM; Gilbert A; Meyer AL; Patriarca PA; Cox MM
    Vaccine; 2009 Dec; 28(2):379-85. PubMed ID: 19879222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The large-scale production of an artificial influenza virus-like particle vaccine in silkworm pupae.
    Nerome K; Sugita S; Kuroda K; Hirose T; Matsuda S; Majima K; Kawasaki K; Shibata T; Poetri ON; Soejoedono RD; Mayasari NL; Agungpriyono S; Nerome R
    Vaccine; 2015 Jan; 33(1):117-25. PubMed ID: 25448101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.